Patents Examined by Jae W Lee
-
Patent number: 11965186Abstract: The present disclosure provides engineered nucleic acid-guided nickases and optimized scaffolds for making rational, direct edits to nucleic acids in live cells.Type: GrantFiled: February 20, 2022Date of Patent: April 23, 2024Assignee: Inscripta, Inc.Inventors: Juhan Kim, Benjamin Mijts
-
Patent number: 11959123Abstract: The present invention aims to provide a novel method that can quantify diaminopimelic acid-containing bacteria in a test sample. The present invention relates to a method of quantifying diaminopimelic acid-containing bacteria in a test sample, including a step of quantifying the diaminopimelic acid-containing bacteria, using, as an index, the amount of diaminopimelic acid derived from the diaminopimelic acid-containing bacteria in the test sample.Type: GrantFiled: March 9, 2020Date of Patent: April 16, 2024Assignee: SUNTORY HOLDINGS LIMITEDInventors: Yosuke Sato, Naoki Kasajima, Toshihiko Fukuda, Masayuki Ida
-
Patent number: 11959111Abstract: The present invention relates to cleaning compositions comprising polypeptides having peptidoglycan degradation activity, as well as use of the cleaning compositions for cleaning of an item such as a textile or a surface.Type: GrantFiled: December 19, 2019Date of Patent: April 16, 2024Assignee: Novozymes A/SInventors: Christian Berg Oehlenschlaeger, Dorotea Raventos Segura, Jesper Salomon, Fabian Barrientos Garcia, Lillian Eva Tang Baltsen, Christian Bech Rosen
-
Patent number: 11959124Abstract: Disclosed are methods and systems for the analysis activity of enzyme disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13 (ADAMTS13) in a sample. The methods and systems disclosed herein can be useful for diagnosis of thrombotic thrombocytopenic purpura in a patient.Type: GrantFiled: November 4, 2020Date of Patent: April 16, 2024Assignee: Laboratory Corporation of America HoldingsInventors: Russell Philip Grant, Christopher Michael Shuford, Meghan Norris Bradley
-
Patent number: 11952557Abstract: The present invention relates to alpha-amylase variants. The present invention also relates to polynucleotides encoding the variants; nucleic acid constructs, vectors, and host cells comprising the polynucleotides; and methods of using the variants.Type: GrantFiled: March 23, 2022Date of Patent: April 9, 2024Assignee: Novozymes A/SInventors: Carsten Andersen, Chakshusmathi Ghadiyaram, Rajendra Kulothungan Sainathan, Padmavathi Balumuri, Padma Venkatachalam Iyer, Iben Damager, Astrid Munch, Sohel Dalal
-
Patent number: 11951231Abstract: A therapeutic agent for intervertebral disc degeneration that contains LASCol obtained by enzymatically cleaving a terminus of collagen.Type: GrantFiled: January 31, 2019Date of Patent: April 9, 2024Assignee: KINKI UNIVERSITYInventors: Takashi Yurube, Yoshiki Takeoka, Koichi Morimoto, Saori Kunii, Kaoru Omae
-
Patent number: 11945853Abstract: Provided herein are polynucleic acids and expression vectors for the expression and secretion of angiotensin peptide fragments (e.g., angiotensin-(1-7)) in probiotic bacteria. Provided herein are also probiotic compositions that enable efficient, cost-effective and patient friendly oral therapeutics for treating diverse pathological conditions that involve the renin-angiotensin system (RAS), e.g., pulmonary hypertension, diabetes, diabetic complications, cardiovascular diseases, and ocular inflammatory and neurodegenerative diseases.Type: GrantFiled: June 14, 2022Date of Patent: April 2, 2024Assignee: UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATEDInventors: Qiuhong Li, Mohan Raizada
-
Patent number: 11938157Abstract: Provided is Lactobacillus paracasei TCI727, deposited in the Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH (DSMZ) with a deposit number of DSM 33756. A method for improving calcium absorption of a subject in need thereof by using the Lactobacillus paracasei TCI727 or metabolites thereof is also provided. The method includes administering to the subject an effective amount of a composition comprising the Lactobacillus paracasei TCI727 or the metabolites thereof.Type: GrantFiled: July 13, 2022Date of Patent: March 26, 2024Assignee: TCI CO., LTD.Inventors: Yung-Hsiang Lin, Chu-Han Huang
-
Patent number: 11939605Abstract: Thermostable Cas9 nucleases. The present invention relates to the field of genetic engineering and more particularly to nucleic acid editing and genome modification. The present invention provides an isolated Cas protein or polypeptide fragment thereof having an amino acid sequence of SEQ ID NO: 1 or a sequence of at least 77% identity therewith. The Cas protein or polypeptide is capable of binding, cleaving, marking or modifying a double stranded target polynucleotide at a temperature in the range 20° C. and 100° C. inclusive. The invention further provides isolated nucleic acid molecules encoding the Cas9 nucleases, expression vectors and host cells. The invention also provides PAM sequences recognized by the Cas protein or polypeptide, The Cas9 nucleases disclosed herein provide novel tools for genetic engineering in general, in particular at elevated temperatures and are of particular value in the genetic manipulation of thermophilic organisms; particularly microorganisms.Type: GrantFiled: January 14, 2022Date of Patent: March 26, 2024Assignees: Wageningen Universiteit, Stichting Voor De Technische WetenschappenInventors: John Van Der Oost, Richard Van Kranenburg, Elleke Fenna Bosma, Ioannis Mougiakos, Prarthana Mohanraju
-
Patent number: 11926843Abstract: Compositions and methods for binding to a target sequence of interest are provided. The compositions find use in cleaving or modifying a target sequence of interest, visualization of a target sequence of interest, and modifying the expression of a sequence of interest. Compositions comprise RNA-guided nuclease polypeptides, CRISPR RNAs, trans-activating CRISPR RNAs, guide RNAs, and nucleic acid molecules encoding the same. Vectors and host cells comprising the nucleic acid molecules are also provided. Further provided are CRISPR systems for binding a target sequence of interest, wherein the CRISPR system comprises an RNA-guided nuclease polypeptide and one or more guide RNAs.Type: GrantFiled: September 17, 2021Date of Patent: March 12, 2024Assignee: LifeEDIT Therapeutics, Inc.Inventors: Alexandra Briner Crawley, Rodolphe Barrangou, Tyson D. Bowen, Michael Coyle, Tedd D. Elich
-
Patent number: 11920130Abstract: The present disclosure provides gene edited modified immune cells or precursors thereof (e.g., gene edited modified T cells) comprising an exogenous T cell receptor (TCR) and/or a chimeric antigen receptor (CAR) having specificity for a target antigen, and an insertion and/or deletion in one or more endogenous gene loci, wherein the endogenous gene loci encode regulators of T cell function, thereby resulting in immune cells having enhanced function. Compositions and methods of treatment are also provided. The present invention provides methods of screening for TCR- or CAR-T cells with enhanced immune function (e.g., T cell efficacy, T cell memory, and/or T cell persistence).Type: GrantFiled: May 12, 2022Date of Patent: March 5, 2024Assignee: The Trustees of the University of PennsylvaniaInventors: Yangbing Zhao, Jiangtao Ren
-
Patent number: 11919919Abstract: This invention relates to a method for the enzymatic synthesis of oligosaccharides, preferably human milk oligosaccharides (HMOs) The method comprises the enzymatic transfer of a glycosyl moiety and subsequent removal of by-products, such as lactose, by nanofiltration using a membrane comprising an active polyamide layer.Type: GrantFiled: December 27, 2021Date of Patent: March 5, 2024Assignee: GLYCOM A/SInventors: Nikolay Khanzhin, Markus Jondelius Hederos
-
Patent number: 11912745Abstract: Proteins, nucleic acids encoding the proteins, compositions comprising the proteins, and methods are provided. The proteins have the ability to be self-targeted to ICAM-1 and, if desired, enzymatically-released at acidic pH. The ICAM-1-targeting peptides are provided as single copies or multiples repeats, and can be separated by linkers from the enzyme segment, from which the ICAM-1 targeting peptides can be released, if desired, at acidic pH. These fusion proteins enhance the activity of the enzyme segment within or liberated from the fusion protein, and provide increased recognition and targeting of diseased organs, transport from the bloodstream across the endothelium into said diseased organ, and intracellular uptake and lysosomal trafficking by cells in them, both in peripheral tissues and the central nervous system. Representative nucleotide and amino acid sequences of these fusion proteins, as well as in vitro, cellular, and in vivo animal data are provided.Type: GrantFiled: January 7, 2022Date of Patent: February 27, 2024Assignee: University of Maryland, College ParkInventors: Silvia Muro, Jing Chen, Melani Solomon, Kevin Gray
-
Patent number: 11898177Abstract: Disclosed are compositions and methods relating to variant maltohexaose-forming alpha-amylases. The variant alpha-amylases are useful, for example, for starch liquefaction and saccharification, for cleaning starchy stains in laundry, dishwashing, and other applications, for textile processing (e.g., desizing), in animal feed for improving digestibility, and for baking and brewing.Type: GrantFiled: July 12, 2021Date of Patent: February 13, 2024Assignee: DANISCO US INC.Inventors: Luis G Cascao-Pereira, David A Estell, Marc Anton Bernhard Kolkman, Harm Mulder
-
Patent number: 11898183Abstract: The present disclosure discloses a recombinant microbe producing podophyllotoxin, or its derivatives, comprising genes encoding phenyl alanine ammonia-lyase (PAL), cinnamate-4-hydroxylate (C4H), 4-coumaroyl CoA-ligase (4CL), hydroxycinnamoyl-CoA quinate hydroxycinnamoyltransferase (HCT), p-coumaroyl quinate 3?-hydroxylase (C3H), caffeoyl CoA O-methyltransferase (CCoAOMT), bifunctional pinoresinol-lariciresinol reductase (DIRPLR), secoisolariciresinol dehydrogenase (SDH), cytochrome P450 oxidoreductase CYP719, O-methyltransferase (OMT), cytochrome P450 oxidoreductase CYP71, and 2-oxoglutarate/Fe(II)-dependent dioxygenase (2-ODD). Also disclosed herein is a method for producing podophyllotoxin or its derivatives. Moreover, a method of treating cancer is also disclosed.Type: GrantFiled: June 10, 2021Date of Patent: February 13, 2024Inventors: Panchapagesa Muthuswamy Murali, Arumbuliyur Sathish Kumar, Shriram Raghavan
-
Patent number: 11898175Abstract: The invention provides methods of using a human acid sphingomyelinase (e.g., olipudase alfa) in treating an abnormal bone condition in acid sphingomyelinase deficiency patients such as low bone density, high bone marrow burden, and other skeletal abnormalities presented in acid sphingomyelinase deficiency patients.Type: GrantFiled: August 22, 2018Date of Patent: February 13, 2024Assignee: Genzyme CorporationInventor: Ana Cristina Scheidt-Puga
-
Patent number: 11891420Abstract: The present disclosure provides a fusion protein useful for treating a non-nuclear organelle associated disorder, such as a genetic disorder, e.g., Friedrich's Ataxia. The fusion protein may comprise a protein of interest to be delivered to a non-nuclear organelle; an organelle targeting sequence (OTS); a cell penetrating peptide (CPP); and a target enhancing sequence (TES); wherein the CPP is capable of interference with delivery of the protein of interest to the non-nuclear organelle; and wherein the TES prevents the interference by the CPP. The fusion protein may also comprise a protein of interest to be delivered to a non-nuclear organelle; a CPP and a TES. The present disclosure also provides methods for treating a non-nuclear organelle associated disorder by administering the fusion protein to a subject in need thereof.Type: GrantFiled: March 26, 2021Date of Patent: February 6, 2024Assignee: Larimar Therapeutics, Inc.Inventors: Joan David Bettoun, Rebecca Wissner
-
Patent number: 11891638Abstract: Disclosed are variants of ACE2, pharmaceutical compositions comprising the variants of ACE2, and treatment methods for reducing Angiotensin II (1-8) plasma levels and/or increasing Angiotensin (1-7) plasma levels in a subject in need thereof. The disclosed variants of ACE2 may include polypeptide fragments of ACE2 having ACE2 activity for converting AngII(1-8) to Ang(1-7). Suitable subjects suitable for the disclosed methods of treatment may include subjects having or at risk for developing diabetic and non-diabetic chronic kidney disease, acute renal failure and its prevention, chronic kidney disease, severe hypertension, scleroderma and its skin, pulmonary, kidney and hypertensive complications, malignant hypertension, renovascular hypertension secondary to renal artery stenosis, idiopathic pulmonary fibrosis, liver fibrosis such as in liver cirrhosis patients, an aortic aneurysm, cardiac fibrosis and remodeling, left ventricular hypertrophy, and an acute stroke.Type: GrantFiled: August 2, 2021Date of Patent: February 6, 2024Assignee: Northwestern UniversityInventors: Daniel Batlle, Jan Wysocki
-
Patent number: 11892449Abstract: Provided is a multivalent protein that targets interaction of SARS-CoV-2 spike receptor binding domain (RBD) with the human angiotensin-converting enzyme 2 (ACE2) receptor protein. The multivalent proteins may also be used to treat subjects having cancer and/or a disease and/or viral infection. Also presented is a multiplex lateral flow test strips for simultaneous detection of the virus and viral antibodies.Type: GrantFiled: November 23, 2022Date of Patent: February 6, 2024Assignee: New York UniversityInventors: Jin Kim Montclare, Farbod Mahmoudinobar, Kamia Punia, Dustin Robert Britton
-
Patent number: 11873322Abstract: A recombinant system for improving genome editing via homologous recombination is disclosed. The system comprising a first nucleic acid sequence encoding a DNA editing agent having a double strand DNA cutting activity and a second nucleic acid sequence encoding a polypeptide capable of increasing homologous recombination in a target cell.Type: GrantFiled: June 25, 2019Date of Patent: January 16, 2024Assignee: Yeda Research and Development Co. Ltd.Inventors: Yosef Shaul, Nina Reuven